| Description | This product TRL345-I8 is a human neutralizing antibody binding CMV gB (Cytomegalovirus glycoprotein B), which is required for viral entry into host cells. It targets antigenic domain 2 site 1 (AD-2S1) of gB and has high binding affinity. TRL345-I8 shows highly potent and broad neutralization ability against CMV. |
| Clonality | Monoclonal |
| Host Species | Human |
| Target Species | Cytomegalovirus (CMV) |
| Epitope | It targets antigenic domain 2 site 1 (AD-2S1), which is a linear epitope at the N-terminus of gB (amino acids 68-81). |
| Neutralization Mechanism | Stabilize the gB AD-2S1 peptide in this conformation |
| Affinity | 4.8 ng/mL |
| Isotype | Human IgG |
| Expression Species | HEK293F or CHO cell line |
| Conjugation | Unconjugated |
| Purity | >95% |
| Endotoxin | <1 EU/mg |
| Form | Liquid |
| Purification | Protein A purified |
| Sterility | 0.2 μM filtered |
| Formulation | PBS, pH 7.4 |
| Preservation | No preservatives |
| Stabilizer | No stabilizers |
| Storage | Store at 4°C within one or two weeks. Store at -20°C for long term. Avoid repeated freeze/thaw cycles. Refer to the COA file for specifics. |
| Application | ELISA; SPR; Neut |
| Application Notes | ELISA: mAb was plated in a 12-point 3-fold serial dilution at a starting concentration of 1 μg/mL. Surface plasmon resonance (SPR): Monoclonal antibody (10 μg/mL) was non-covalently captured on the surface of a Series S Sensor Chip Protein A by injection for 60 s at a flow rate of 5 μL/min. Neutralization assay (Neut): mAb was coincubated at a starting concentration of 50 μg/mL (50 μg/mL to 22.9 ng/mL). Virus and antibody mixtures were added to cells and allowed to incubate for 16 to 24 h at 37°C. |
| ELISA | Enzyme-Linked Immunosorbent Assay Protocol |
| WB | Western Blot Protocol |
| FC | Flow Cytometry Protocol |
| Target | CMV gB |
| Alternative Name | Cytomegalovirus glycoprotein B |
| Research Area | Infectious Disease |
| Related Disease | Permanent hearing loss; Cognitive impairment; Retinitis; Cerebral palsy |
